The use of melanosomal proteins in the immunotherapy of melanoma

Journal of Immunotherapy

Volumn 21, Issue 4, 1998, Pages 237-246

  Kawakami, Yutaka ^a   Robbins, Paul F ^a   Wang, Rong Fu ^a   Parkhurst, Maria ^a   Kang, Xiaoqiang ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

GP100; Immunotherapy; MART 1; Melanoma antigens; Subdominant epitopes

Indexed keywords

BETA CATENIN; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; MART 1 ANTIGEN[27-35]; MELAN A; MELANOMA ANTIGEN; MELANOSOMAL PROTEIN; MUTANT PROTEIN; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; GENE ISOLATION; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MELANOSOME; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REJECTION; VIRUS RECOMBINANT;

EID: 0031870624     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199807000-00001     Document Type: Article

References (75)

1. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N Engl J Med 1988;319:1676-80.
2. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. JNCI 1995;86:1159-66.
3. Kawakami Y, Robbins PF, Wang RF, Rosenberg SA. Identification of melanoma antigens recognized by T lymphocytes and their use in the immunotherapy of cancer. In: Devita VT, Heilman S, Rosenberg SA, eds. Principle and practice of oncology, update. Philadelphia: Lippincott-Raven, 1997:1-20.
4. Robbins PF, Kawakami Y. Human tumor antigens recognized by T cells. Curr Opin Immunol 1996;8:628-36.
5. Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA. Shared human melanoma antigens. Recognition by tumor infiltrating lymphocytes in HLA-A2.1 transfected melanomas. J Immunol 1992;148:638-43.
6. O’Neil BH, Kawakami Y, Restifo NP, Bennink JR, Yewdell JW, Rosenberg SA. Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. J Immunol 1993;151:1410-18.
7. Anichini A, Maccalli C, Mortarini R, et al. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2 restricted cytotoxic T cell clones from melanoma patients. J Exp Med 1993;177:989-98.
8. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lemer AB. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983;9:689-95.
9. Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992;10:1338-43.
10. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be target for cancer immunotherapy. J lmmunother 1996; 19:81-4.
11. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci VSA 1994;91:6458-62.
12. Kawakami Y, Eliyahu S, Delgaldo CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-9.
13. Robbins PF, El-Gamil M, Kawakami Y, Stevens E, Yannelli J, Rosenberg SA. Recognition of tyrosinase by tumor infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 1994;54:3124-6.
14. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 1995;181:799-804.
15. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996;184:2207-16.
16. Kawakami Y, Battles JK, Kobayashi T, et al. Production of recombinant MART-1 proteins and specific anti-MART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. J Immunol Methods 1997;202:13-25.
17. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-95.
18. Kang XQ, Kawakami Y, Sakaguchi K, et al. Identification of a tyrosinase epitope reocognized by HLA-A24 restricted tumor-infiltrating lymphocytes. J Immunol 1995;155:1343-8.
19. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994;91: 9461-5.
20. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 1996;183:1965-71.
21. Brichard VG, Herman J, Van Pel A, et al. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. EurJ Immunol 1996;26:224-30.
22. Cox AL, Skipper J, Cehn Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-9.
23. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gplOO associated with in vivo tumor regression. J Immunol 1995;154:3961-8.
24. Tsai V, Southwood S, Sidney J, et al. Induction of subdominant CTL epitopes of the gplOO melanoma associated tumor antigen by primary in vitro immunization with peptide pulsed dendritic cells. J Immunol 1997;158:1796-802.
25. Skipper JCA, Kittlesen DJ, Hendrickson RC, et al. Shared epitopes for HLA-A3 restricted melanoma reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J Immunol 1996; 157:5027-33.
26. Robbins PF, El-Gamil M, Li YF, et al. A mutated P-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183:1185-92.
27. Kawakami Y, Rosenberg S. T-cell recognition of self peptides as tumor rejection antigens. Immunol Res 1995;15:179-90.
28. Schoenberger SP, Sercarz EE. Harnessing self-reactivity in cancer immunotherapy. Semin Immunol 1996;8:303-9.
29. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-65.
30. Van Pel A, Van der Brugen P, Coulie PG, et al. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 1995;145:229-50.
31. Coulie PG, Lehmann F, Lethe B, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 1995;92: 7976-80.
32. Wolfel T, Hauer M, Schneider J, et al. A p161NK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-4.
33. Anichini A, Mortarini R, Maccalli C, et al. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol 1996;156:208-17.
34. Wiedenfeld EA, Femandez-Vina M, Berzofsky JA, Carbone DP. Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A-0201 peptide consensus motif. Cancer Res 1994;54:1175-7.
35. Wang RF, Parkhurst M, Kawakami Y, Robbins PF, Rosenberg SA. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med 1996; 183: 1131-40.
36. Robbins PF, El-Gamil M, Li YF, Fitzgerald E, Kawakami Y, Rosenberg SA. The intronic region of an imcompletely-spliced gplOO gene transcript encodes an epitope recognized by melanoma reactive tumor infiltrating lymphocytes. J Immunol (in press).
37. Skipper JCA, Hendrickson RC, Gulden PH, et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from post-translational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996;183:527-34.
38. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52.
39. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3:37-44.
40. + cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo, lnt J Cancer 1996;66:470-6.
41. Bloom MB, Lalley DP, Robbins PF, et al. Identification of TRP2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997;58:177-210.
42. Zhai Y, Kawakami Y, Yang JC, et al. Antigen-specific tumor vaccines: development and characterization of recombinant adenoviruses encoding MART-1 or gp100 for cancer therapy. J Immunol 1995;156:700-10.
43. Hara I, Takechi Y, Houghton AN. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the Brown locus protein. J Exp Med 1995;182:1609-14.
44. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997; 185:833-41.
45. Salgaller M, Marincola F, Rivoltini L, Kawakami Y, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp100 by antigen specific peripheral blood lymphocytes stimulated with synthetic peptides. Cancer Res 1995;55:4972-9.
46. Rosenberg SA. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. JNCI 1996;88:1635-44.
47. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-84.
48. Hu J, Kindsvogel W, Busby S, Bailey MC, Shi Y, Greenberg PD. An evaluation of the potential to use tumor-associated antigens as targets for anti-tumor T cell therapy using transgenic mice expressing a retroviral antigen in normal lymphoid tissues. J Exp Med 1993;177:1681-90.
49. Salgaller ML, Weber JS, Koenig S, Yanelli JR, Rosenberg SA. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol Immunother 1994;39:105-16.
50. Marchand M, Weynants P, Rankin E, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Ini J Cancer 1996;63:883-5.
51. Boon T. Toward a genetic analysis of tumor rejection antigens. Adv Cancer Res 1992;58:177-210.
52. Mumberg D, Wick M, Schreiber H. Unique tumor antigens redefined as mutant tumor-specific antigens. Semin Immunol 1996;8: 289-93.
53. Srivastava PK. Do human cancers express shard protective antigens? or the necessity of remembrance of things past. Semin Immunol 1996;8:295-302.
54. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cell engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulate potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90: 3539-43.
55. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
56. Udono H, Srivastava P. Comparison of tumor specific immunogenicities of stress-induced proteins gp96, Hsp90, and Hsp80. J Immunol 1994;152:5398-403.
57. Castelli C, Storkus WJ, Maeurer MJ, et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 1995;181: 363-8.
58. Irvine KR, Restifo NP. The next wave of recombinant and synthetic anticancer vaccines. Semin Cancer Biol 1995;6:337-47.
59. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996;2:52-8.
60. Irvine K, Rao J, Rosenberg SA, Restifo NP. Cytokine enhancement of DNA immunization leads to treatment of established pulmonary metastases. J Immunol 1996;156:238-45.
61. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996;56:4749-57.
62. Reeves ME, Royal RE, Lam JS, Rosenberg SA, Hwu P. Retroviral transduction of human dendritic cells with a tumor associated antigen gene. Cancer Res 1996;56:5672-7.
63. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995; 269:1585-8.
64. Parkhurst MR, Salgaller M, Southwood S, et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A0201 binding residues. J Immunol 1996;157:2539-48.
65. Kang X, Robbins PF, Fitzgerald EB, Wang RF, Rosenberg SA, Kawakami Y. Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-MHC class I fusion proteins. Cancer Res 1997;57:202-5.
66. Bronte V, Tsung K, Rao JB, et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol 1995;154:5282-92.
67. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
68. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996;8:271-80.
69. Salgaller ML. Monitoring of cancer patients undergoing active or passive immunotherapy. J Immunother 1997;20:1-14.
70. + T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1 binding melanoma and viral peptide antigens. J Immunol Methods 1996;191:131-42.
71. Sensi M, Traversari C, Radrizzani M, et al. Cytotoxic T lymphocyte clones from different patients display limited T-cell receptors variable gene usage in HLA-A2 restricted recognition of Melan/Mart-1 melanoma antigen. Proc Natl Acad Sci USA 1995;92: 5674-8.
72. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yanelli JR, Rosenberg SA. Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. JNC1 1996;88:100-8.
73. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;10:487-94.
74. Mizoguchi H, O’Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992;258:1795-8.
75. Hahne M, Rimoldi D, Schroter P, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-6.